Matinas BioPharma Holdings (MTNB) Assets Average (2014 - 2026)

Matinas BioPharma Holdings (MTNB) has 13 years of Assets Average data on file, last reported at $6.5 million in Q1 2026.

• Assets Average for Q1 2026 came in at $6.5 million, down 46.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.5 million (down 46.98% YoY), and the FY2025 annual result was $9.9 million, down 47.41% from the prior year.
• Assets Average declined to $6.5 million in Q1 2026 per MTNB's latest filing, from $8.5 million in the prior quarter.
• Over five years, Assets Average peaked at $58.6 million in Q1 2022 and troughed at $6.5 million in Q1 2026.
• A 5-year average of $28.2 million and a median of $22.5 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2025: Assets Average declined 18.29% in 2022, then plunged 53.01% in 2025.
• A 5-year view of Assets Average shows it stood at $46.2 million in 2022, then slumped by 40.57% to $27.4 million in 2023, then slumped by 39.49% to $16.6 million in 2024, then tumbled by 49.11% to $8.5 million in 2025, then fell by 22.61% to $6.5 million in 2026.
• Business Quant data shows MTNB's Assets Average at $6.5 million in Q1 2026, $8.5 million in Q4 2025, and $10.6 million in Q3 2025.